Why these 4 ASX shares are sinking lower today


In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is on course to finish the day in the red. At the time of writing the benchmark index is down 0.1% to 5,721.4 points.

Four shares falling more than most today are listed below. Here’s why they are sinking lower:

The Ausdrill Limited (ASX: ASL) share price is down almost 7% to $1.32 despite there being no news out of the diversified mining services company. At one stage today Ausdrill’s shares fell to a 52-week low of $1.26. The company’s shares have come under significant selling pressure since it announced the acquisition of Barminco and the loss of a mining contract at the Edikan gold mine in August.

The Accent Group Ltd (ASX: AX1) share price has dropped 4.5% to $1.28. I suspect that a spot of profit taking is happening today after Accent Group’s shares rocketed higher last week following its positive AGM update. One broker that thinks this is a buying opportunity is Morgans. Earlier this week it upgraded the footwear retailer’s shares to an add rating with a $1.46 price target.

The Admedus Ltd (ASX: AHZ) share price has returned from its suspension and crashed 55% lower to 6 cents. Admedus’ shares have been suspended since the start of August whilst it went through a recapitalisation plan. This morning it launched a partially underwritten entitlement offer to raise up to $20.2 million before costs. The capital raised from this rights issue will provide funding for Admedus to consolidate and further develop its ADAPT portfolio and position itself for the development of new products in 2019.

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has dropped 7% lower to $1.18. This morning the biopharmaceutical company was the subject of another broker note out of Morgans. According to the note, the broker has initiated coverage on Paradigm with a reduce (sell) rating and 89 cents price target. The broker believes that high levels of trial success relating to the repurposing of pentosan polysulfate sodium have been priced in already.

5 Companies we like better than Paradigm Biopharmaceuticals

When ace stock picker Scott Phillips has a buy recommendation, history suggests it can pay to listen.

Scott recently revealed what he believes are the five best ASX stocks for investors to buy right now… and Paradigm Biopharmaceuticals wasn’t one of them! That’s right — he thinks these 5 stocks are even better buys.

See the 5 stocks

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Accent Group. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.